Anika Therapeutics Inc (ANIK) Analysts See $0.50 EPS

July 17, 2017 - By Clifton Ray

 Anika Therapeutics Inc (ANIK) Analysts See $0.50 EPS
Investors sentiment decreased to 1.01 in Q4 2016. Its down 0.25, from 1.26 in 2016Q3. It dived, as 17 investors sold Anika Therapeutics Inc shares while 53 reduced holdings. 20 funds opened positions while 51 raised stakes. 10.86 million shares or 0.92% less from 10.97 million shares in 2016Q3 were reported.
The Massachusetts-based Panagora Asset Management has invested 0.01% in Anika Therapeutics Inc (NASDAQ:ANIK). Morgan Stanley invested 0% of its portfolio in Anika Therapeutics Inc (NASDAQ:ANIK). Louisiana State Employees Retirement Sys stated it has 0.01% of its portfolio in Anika Therapeutics Inc (NASDAQ:ANIK). Eaton Vance Mngmt reported 6,013 shares. Guggenheim Lc, a Illinois-based fund reported 4,779 shares. Renaissance Limited Co stated it has 166,800 shares or 0.01% of all its holdings. 21,315 are held by Credit Suisse Ag. Comerica Bankshares invested 0.01% of its portfolio in Anika Therapeutics Inc (NASDAQ:ANIK). Nationwide Fund Advsr accumulated 21,865 shares. Tudor Invest Et Al has invested 0.02% in Anika Therapeutics Inc (NASDAQ:ANIK). 22,400 are owned by Pdts Prtn Lc. Cadence Cap Mgmt Ltd Liability has invested 0.09% in Anika Therapeutics Inc (NASDAQ:ANIK). Earnest Ptnrs Limited Liability Com holds 0% or 1,500 shares. Swiss National Bank stated it has 24,300 shares. Teachers Retirement Systems Of The State Of Kentucky has 28,610 shares for 0.02% of their portfolio.

Since February 22, 2017, it had 0 insider buys, and 3 sales for $833,696 activity. 4,000 shares were sold by Cheung Sylvia, worth $196,096. Thompson Jeffery S also sold $508,274 worth of Anika Therapeutics Inc (NASDAQ:ANIK) on Friday, May 19. On Wednesday, February 22 LAND RAYMOND J sold $129,326 worth of Anika Therapeutics Inc (NASDAQ:ANIK) or 2,635 shares.

Analysts await Anika Therapeutics Inc (NASDAQ:ANIK) to report earnings on July, 26. They expect $0.50 earnings per share, down 12.28 % or $0.07 from last year’s $0.57 per share. ANIK’s profit will be $7.32 million for 23.24 P/E if the $0.50 EPS becomes a reality. After $0.37 actual earnings per share reported by Anika Therapeutics Inc for the previous quarter, Wall Street now forecasts 35.14 % EPS growth. The stock increased 0.76% or $0.35 during the last trading session, reaching $46.47. About 75,267 shares traded. Anika Therapeutics Inc (NASDAQ:ANIK) has risen 4.53% since July 18, 2016 and is uptrending. It has underperformed by 12.17% the S&P500.

Anika Therapeutics Inc (NASDAQ:ANIK) Ratings Coverage

Among 3 analysts covering Anika Therapeutics (NASDAQ:ANIK), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Anika Therapeutics had 6 analyst reports since July 30, 2015 according to SRatingsIntel. On Friday, February 26 the stock rating was maintained by Northland Capital with “Outperform”. As per Wednesday, April 27, the company rating was downgraded by Northland Capital. As per Thursday, July 30, the company rating was maintained by Northland Capital. The rating was initiated by First Analysis with “Equal Weight” on Friday, August 28. The company was initiated on Monday, October 12 by Barrington Research. The company was upgraded on Wednesday, August 26 by Zacks.

Anika Therapeutics, Inc. is an orthopedic medicines company. The company has market cap of $680.26 million. The Firm is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid technology. It has a 22.46 P/E ratio. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA scaffold to aid cartilage repair and regeneration.

More notable recent Anika Therapeutics Inc (NASDAQ:ANIK) news were published by: which released: “4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings” on July 17, 2017, also with their article: “Anika Announces $5 Million Milestone Payment from US Commercial Sales of MONOVISC” published on July 17, 2017, published: “Anika Announces Publication of Phase III Data Demonstrating the Efficacy and …” on May 22, 2017. More interesting news about Anika Therapeutics Inc (NASDAQ:ANIK) were released by: and their article: “Anika Therapeutics, Inc., (Nasdaq: ANIK) to Ring The Nasdaq Stock Market …” published on February 27, 2017 as well as‘s news article titled: “Anika Therapeutics launches supplemental late-stage study of CINGAL for …” with publication date: May 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.